Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome

References

• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology20061305 1480 149116678561
   PubMed Web of Science ®Google Scholar
• DrossmanDACamilleriMMayerEAWhiteheadWEAGA technical review on irritable bowel syndromeGastroenterology20021236 2108 213112454866
   PubMed Web of Science ®Google Scholar
• CanavanCWestJCardTThe epidemiology of irritable bowel syndromeClin Epidemiol20146 71 8024523597
   PubMed Web of Science ®Google Scholar
• SuAMShihWPressonAPChangLCharacterization of symptoms in irritable bowel syndrome with mixed bowel habit patternNeurogastroenterol Motil2014261 36 4523991913
   PubMed Web of Science ®Google Scholar
• DupontHLReview article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targetsAliment Pharmacol Ther20143910 1033 104224665829
   PubMed Web of Science ®Google Scholar
• OwyangCIrritable Bowel SyndromeKasperDFauciAHauserSLongoDJamesonJLoscalzoJHarrison’s Principles of Internal Medicine19th edNew YorkMcGraw-Hill2014 Available from: http://accesspharmacy.mhmedical.com/content.aspx?bookid=1130&sectionid=79748082Accessed June 14, 2017
   Google Scholar
• FordACMoayyediPLacyBETask Force on the Management of Functional Bowel DisordersAmerican college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipationAm J Gastroenterol2014109Suppl 1 S2 S2625091148
   PubMed Web of Science ®Google Scholar
• WeinbergDSSmalleyWHeidelbaughJJSultanSAmerican Gastroenterological AssociationAmerican gastroenterological association institute guideline on the pharmacological management of irritable bowel syndromeGastroenterology20141475 1146 114825224526
   PubMed Web of Science ®Google Scholar
• LucakSChangLHalpertAHarrisLACurrent and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practiceTherap Adv Gastroenterol2017102 253 275
   PubMed Web of Science ®Google Scholar
• CheyWDKurlanderJEswaranSIrritable bowel syndrome: a clinical reviewJAMA20153139 949 95825734736
   PubMed Web of Science ®Google Scholar
• CashBDEpsteinMSShahSMA novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptomsDig Dis Sci2016612 560 57126319955
   PubMed Web of Science ®Google Scholar
• CampanelliCMAmerican Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc2013604 616 631
   Web of Science ®Google Scholar
• FordACQuigleyEMLacyBEEffect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysisAm J Gastroenterol20141099 1350 136524935275
   PubMed Web of Science ®Google Scholar
• XieCTangYWangYEfficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysisPLoS One2015108 e012781526252008
   PubMed Web of Science ®Google Scholar
• GhoshalUCShuklaRGhoshalUSmall intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomyGut Liver2017112 196 20828274108
   PubMed Web of Science ®Google Scholar
• ZhengYYuTTangYEfficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trialsPLoS One2017123 1 21
   Web of Science ®Google Scholar
• FoodUSAdministrationDrugApproved Risk Evaluation and Mitigation Strategies (REMS) Available from: https://www.accessdata.fda.gov/scripts/cder/rems/Accessed June 5, 2017
   Google Scholar
• GarsedKChernovaJHastingsMA randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoeaGut20146310 1617 162524334242
   PubMed Web of Science ®Google Scholar
• Viberzi® (Eluxadoline) Tablets [Prescribing Information]Irvine, CAAllergen USA Inc2017
   Google Scholar
• DavenportJMCovingtonPBonifacioLMcIntyreGVenitzJEffect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadolineJ Clin Pharmacol2015555 534 54225491493
   PubMed Web of Science ®Google Scholar
• FantRVHenningfieldJECashBDDoveLSCovingtonPSEluxadoline demonstrates a lack of abuse potential in Phase 2 and 3 studies of patients with irritable bowel syndrome with diarrheaClin Gastroenterol Hepatol2017157 1021 102928167156
   PubMed Web of Science ®Google Scholar
• Levy-CoopermanNMcIntyreGBonifacioLAbuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonistJ Pharmacol Exp Ther20163593 471 48127647873
   PubMed Web of Science ®Google Scholar
• DoveLSLemboARandallCWEluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 studyGastroenterology20131452 329 33823583433
   PubMed Web of Science ®Google Scholar
• LemboAJLacyBEZuckermanMJEluxadoline for irritable bowel syndrome with diarrheaN Engl J Med20163743 242 25326789872
   PubMed Web of Science ®Google Scholar
• LacyBECheyWDCashBDLemboAJDoveLSCovingtonPSEluxadoline efficacy in IBS-D patients who report prior loperamide useAm J Gastroenterol20171126 924 93228417992
   PubMed Web of Science ®Google Scholar
• CheyWDDoveLSAndraeDACovingtonPSEarly response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studiesAliment Pharmacol Ther20174510 1319 132828326568
   PubMed Web of Science ®Google Scholar
• CashBDLacyBESchoenfeldPSDoveLSCovingtonPSSafety of eluxadoline in patients with irritable bowel syndrome with diarrheaAm J Gastroenterol20161122 365 37427922029
   PubMed Web of Science ®Google Scholar
• GastroenterologyPharm Lett2017 33 Available from: http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&cs=FACULTY&s=PL&pt=6&fpt=31&dd=330509&pb=PL&cat=4021Accessed July 7, 2017
   Google Scholar
• ThoeniRFThe revised a Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatmentRadiology20122623 751 76422357880
   PubMed Web of Science ®Google Scholar
• Levy-CoopermanNMcIntyreGBonifacioLAbuse potential and pharmacodynamic characteristics of oral and intranasal eluxado-line, a mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonistJ Pharmacol Exp Ther20163593 Suppl 1 471 48127647873
   PubMed Web of Science ®Google Scholar
• National Institute on Alcohol Abuse and AlcoholismAlcohol Facts and Statistics Available from: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-and-statistics. Published 2017Accessed June 13, 2017
   Google Scholar
• BarnesDSGallbladder and Biliary Tract DiseaseCleveland Clinic Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hepatology/gallbladder-biliary-tract-disease/. Published 2010Accessed June 13, 2017
   Google Scholar
• US Food and Drug AdministrationFDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Available from: https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm. Published 2017Accessed June 14, 2017
   Google Scholar
• EluxadolineLexiComp Available from: https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/5680923#feeAccessed June 14, 2017
   Google Scholar